CARM
Carisma Therapeutics Inc.Company with tickers: CARM
CIK
1485003
Shares Outstanding
41,845,078
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $45,300,000 | USD | 2025-09-30 | 10-Q | 2025-11-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $1,436,000 | USD | 2025-09-30 | 10-Q | 2025-11-12 |
| Research & Development | $197,000 | USD | 2025-09-30 | 10-Q | 2025-11-12 |
| Operating Income | $43,814,000 | USD | 2025-09-30 | 10-Q | 2025-11-12 |
| Net Income | $44,717,000 | USD | 2025-09-30 | 10-Q | 2025-11-12 |
| EPS (Basic) | $1.07 | USD/shares | 2025-09-30 | 10-Q | 2025-11-12 |
| EPS (Diluted) | $1.07 | USD/shares | 2025-09-30 | 10-Q | 2025-11-12 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2024-12-31 |
|---|---|
| Option Right Collaboration Revenues | $3,800,000 |
| Milestones | $2,000,000 |